Browsing Institut de Recerca Biomèdica de Lleida (IRBLleida) by Author "Salud Salvia, Maria Antonieta"
Now showing items 1-7 of 7
-
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Loupakis, Fotios; Stein, Alexander; Ychou, Marc; Hermann, Frank; Salud Salvia, Maria Antonieta; Österlund, Pia (Springer, 2016)Colorectal cancer is the third most common cancer worldwide. A significant proportion of patients presents with unresectable metastatic disease or develops metachronous metastases following surgical resection of the primary ... -
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)
Fernandez-Plana, Julen; Pericay, Carles; Quintero, Guillermo; Alonso, Vicente; Salud Salvia, Maria Antonieta; Mendez, Miguel; Salgado, Mercedes; Saigi, Eugeni; Cirera, Luis (BMC, 2014)Background: This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS ... -
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
Feliu, Jaime; Safont, M. J.; Salud Salvia, Maria Antonieta; Losa, F.; García-Girón, C.; Bosch, Carlos; Escudero, P.; López, R.; Madroñal, C.; Bolaños, M.; Gil, M.; Llombart, A.; Castro-Carpeño, J.; González-Barón, M. (Nature Publishing Group; Cancer Research UK, 2010)BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based ... -
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
Garcia-Alfonso, Pilar; Chaves, Manuel; Muñoz, Andrés; Salud Salvia, Maria Antonieta; García-Gonzalez, Maria; Grávalos, Cristina; Massuti, Bartomeu; González-Flores, Encarna; Queralt, Bernardo; López-Ladrón, Amelia; Losa, F.; Gómez, Maria Jose; Oltra, Amparo; Aranda, Enrique (BioMed Central, 2015)Background: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability ... -
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab treated patients with metastatic colorectal cancer
Feliu, Jaime; Salud Salvia, Maria Antonieta; Safont, M. J.; García-Girón, C.; Aparicio, Jorge; Losa, F.; Bosch, Carlos; Escudero, P.; Casado, Enrique; Jorge, Monica; Bohn, Uriel; Pérez-Carrión, Ramon; Carmona, Alberto; Custodio, Ana B.; Maurel, Joan (Public Library of Science, 2015)Background Studies suggest a relationship between hypertension and outcome in bevacizumab-treated patients with metastatic colorectal cancer (mCRC). We performed a retrospective analysis of two phase II studies (BECA ... -
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
Feliu, Jaime; Salud Salvia, Maria Antonieta; Safont, M. J.; García-Girón, C.; Aparicio, Jorge; Serra, O.; Vera, Ruth; Casado, Enrique; Jorge, Monica; Escudero, P.; Bosch, Carlos; Bohn, Uriel; Pérez-Carrión, Ramon; Carmona, Alberto; Martínez-Marín, V.; Maurel, Joan (Cancer Research UK, 2014)Background: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the ... -
Identifying thoracic malignancies through pleural fluid biomarkers: a predictive multivariate model
Porcel Pérez, José Manuel; Esquerda, Aureli; Martínez Alonso, Montserrat; Bielsa Martín, Silvia; Salud Salvia, Maria Antonieta (Wolters Kluwer Health, 2016-03-01)The diagnosis of malignant pleural effusions may be challenging when cytological examination of aspirated pleural fluid is equivocal or noncontributory. The purpose of this study was to identify protein candidate biomarkers ...